APPROVED FOR THE TREATMENT OF IPF AND SSc-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
PCCP Midyear Convention Lecture - Progressive Pulmonary Fibrosis
Document ID: PC-PH-104250
26/10/2022
Author: Boehringer Ingelheim
RELATED CONTENT
PC-PH-104250
Production date: October 2022
Production date: October 2022
